Form 4 for ABT Abbott Laboratories
Accepted 2023-05-02 00:00:00 ET · period of report 2023-04-28 · accession 0001415889-23-007139 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-02 | 2023-04-28 | ABT | STARKS DANIEL J | Dir | A - Grant | $0.00 | +1,816 | 6.88M | +0.0% | $0 |
| DM | 2023-05-02 | 2023-05-02 | ABT | STARKS DANIEL J | Dir | S - Sale | $111.02 | -50.0K | 6.83M | -0.7% | -$5.55M |
| D | 2023-05-02 | 2023-04-28 | ABT | STARKS DANIEL J | Dir | A - Grant | $0.00 | +8,136 | 8,136 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2023-04-28 | A | A | 1,816 | $0.00 | 6,875,316 | D | — | — | (F1) These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| 2 | Common | Common shares without par value | 2023-05-02 | S | D | 3,452 | $111.75 | 6,825,316 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.58 to $111.90, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 3 | Common | Common shares without par value | 2023-05-02 | S | D | 46,548 | $110.97 | 6,828,768 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.51 to $111.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 4 | Derivative | Option (right to buy) | 2023-04-28 | A | A | 8,136 | $0.00 | 8,136 | D | $110.12 · 2023-04-28 to 2033-04-27 | 8,136 Common Shares | (F5) Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |